Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the research and development of immune-system directed treatments. The company's primary goal is to harness the body's natural defense mechanisms to combat cancer, inflammation, and infectious diseases. Provectus's flagship product, PV-10, is an investigational oncology drug derived from Rose Bengal, which is designed to target and destroy cancerous tumors while stimulating a systemic immune response against cancer cells. This innovative approach positions the company within the oncology sector, aiming to provide new therapeutic options for patients with limited treatment choices. Situated within the biopharmaceutical industry, Provectus plays a vital role in pioneering novel treatments that could significantly impact healthcare and improve patient outcomes in cancer therapy. Through its progressive research initiatives, Provectus Biopharmaceuticals continues to contribute to scientific discovery and the advancement of cancer treatment methodologies.